Assessment of the SFlt-1 and sFlt-1/25(OH)D Ratio as a Diagnostic Tool in Gestational Hypertension (GH), Preeclampsia (PE), and Gestational Diabetes Mellitus (GDM) by Walentowicz-Sadlecka, Malgorzata & Arias Moliz, María Teresa
Research Article
Assessment of the SFlt-1 and sFlt-1/25(OH)D Ratio as a
Diagnostic Tool in Gestational Hypertension (GH), Preeclampsia
(PE), and Gestational Diabetes Mellitus (GDM)
Malgorzata Walentowicz-Sadlecka ,1 Piotr Domaracki ,1 Pawel Sadlecki ,1
Joanna Siodmiak,2 Marek Grabiec,1 Pawel Walentowicz ,1 Maria Teresa Arias Moliz,3
and Grazyna Odrowaz-Sypniewska1
1Department of Obstetrics and Gynecology, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University,
ul. Ujejskiego 75, Bydgoszcz 85-168, Poland
2Department of Laboratory Medicine, L. Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, M. Curie
Skłodowskiej 9, Bydgoszcz 85-094, Poland
3Department of Microbiology, University of Granada, Avda. del Hospicio, 18071 Granada, Spain
Correspondence should be addressed to Malgorzata Walentowicz-Sadlecka; walentowiczm@cm.umk.pl
Received 23 January 2019; Revised 3 May 2019; Accepted 17 June 2019; Published 6 August 2019
Guest Editor: Zhongjie Shi
Copyright © 2019 Malgorzata Walentowicz-Sadlecka et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Background. Placental soluble fms-like tyrosine kinase-1 (sFlt-1), an antagonist of vascular endothelial growth factor, is considered
an etiological factor of endothelial damage in pregnancy pathologies. An increase in the sFlt-1 level is associated with alterations of
endothelial integrity. In contrast, vitamin D exerts a protective eﬀect and low concentrations of 25(OH)D may have an adverse
eﬀect on common complications of pregnancy, such as gestational hypertension (GH), preeclampsia (PE), and gestational
diabetes mellitus (GDM). The aim of this study was to analyze the levels of sFlt-1 in Polish women with physiological
pregnancies and pregnancies complicated by GH, PE, and GDM. Moreover, we analyzed relationships between the maternal
serum sFlt-1 level and the sFlt-1 to 25(OH)D ratio and the risk of GH and PE. Material and Methods. The study included 171
women with complicated pregnancies; among them are 45 with GH, 23 with PE, and 103 with GDM. The control group was
comprised of 36 women with physiological pregnancies. Concentrations of sFl-1 and 25(OH)D were measured before delivery,
with commercially available immunoassays. Results. Women with GH diﬀered signiﬁcantly from the controls in terms of their
serum sFlt-1 levels (5797 pg/ml vs. 3531 pg/ml, p = 0 0014). Moreover, a signiﬁcant diﬀerence in sFlt-1 concentrations was found
between women with PE and those with physiological pregnancies (6074 pg/ml vs. 3531 pg/ml, p < 0 0001). GDM did not exert
a statistically signiﬁcant eﬀect on serum sFlt-1 levels. Both logistic regression and ROC analysis demonstrated that elevated
concentration of sFlt-1 was associated with greater risk of GH (AUC = 0 70, p = 0 0001) and PE (AUC = 0 82, p < 0 0001). Also,
the sFlt-1 to 25(OH)D ratio, with the cutoﬀ values of 652 (AUC = 0 74, p < 0 0001) and 653 (AUC = 0 88, p < 0 0001),
respectively, was identiﬁed as a signiﬁcant predictor of GH and PE. Conclusions. Determination of the sFlt-1/25(OH)D ratio
might provide additional important information and, thus, be helpful in the identiﬁcation of patients with PE and GH,
facilitating their qualiﬁcation for intensive treatment and improving the neonatal outcomes.
1. Introduction
Preeclampsia (PE) and gestational diabetes mellitus (GDM)
are two of the most important causes of pregnancy complica-
tions. The incidence of both these conditions has been grad-
ually increasing worldwide, up to 5% for PE and up to 13%
for GDM [1, 2]. Gestational hypertension (GH) is a leading
cause of morbidity and mortality in pregnant women,
fetuses, and newborns [3]. PE manifests after 20 weeks of
gestation and constitutes a life-threatening condition for
Hindawi
Disease Markers
Volume 2019, Article ID 5870239, 10 pages
https://doi.org/10.1155/2019/5870239
both fetuses and pregnant women. The prevalence of GH
increases with age and is higher in overweight and obese
women [4].
The term “diabetes” refers to a group of metabolic dis-
eases associated with hyperglycemia resulting from
impaired secretion or function of insulin [5]. To be classi-
ﬁed as gestational, diabetes needs to be detected for the
ﬁrst time during pregnancy [6]; the proportion of preg-
nancies complicated by GDM is estimated at 3-12% [7].
Aside from patient’s age, the risk of GDM increases with
body weight and is particularly high in obese women. A
British population-based study demonstrated that the
proportion of obese pregnant women has nearly doubled,
from 9-10% in early 1990’s to 16-19% in the ﬁrst years
of the 21st century [8]. Pregnant women with GDM are
at increased risk of GH and PE; insulin resistance and
hyperglycemia are associated with greater oxidative stress
which contributes to endothelial dysfunction in blood vessels
and predisposes to hypertension [9].
An antiangiogenic factor, soluble fms-like tyrosine kinase
1 (sFlt-1), was shown to play an important role in the patho-
genesis of many conditions related to vascular endothelium.
sFlt-1 is an endogenous inhibitor of vascular endothelial
growth factor (VEGF). Binding to VEGF proteins, sFlt-1
reduces their pool that can interact with transmembrane
receptors and, hence, attenuates the VEGF-mediated signal-
ing [10]. This contributes to impairment of angiogenesis
and greater vascular permeability leading to the loss of
serum proteins [11]. Available evidence suggests that ele-
vated levels of sFlt-1 might be associated with the occurrence
of PE and other pregnancy complications, such as intrauter-
ine growth restriction, preterm labor, and miscarriage [12].
Importantly, an increase in the sFlt-1 level can be observed
well before the ﬁrst clinical manifestations of gestational
complications, which implies that this parameter could be
used to distinguish between physiological and high-risk
pregnancies [13].
Vitamin D deﬁciency is associated with endothelial
dysfunction. Epidemiological studies demonstrated a link
between the low maternal level of vitamin D and higher inci-
dence of GH and showed that deﬁciency of this vitamin may
be an independent risk factor of PE [14]. Activation of
vitamin D receptors is known to promote VEGF expression;
further, an adequate level of vitamin D and appropriate
expression of vitamin D receptors (VDRs) were shown to
be fundamental for angiogenic function of endothelial cells
and their protection against oxidative damage [15]. In our
previous study, we found a signiﬁcant association between
the low serum level of vitamin D and the risk of preeclamp-
sia; the area under ROC curve (AUC) for serum vitamin D
as a predictor of PE was 70.3% [16].
The aim of this study was to analyze serum levels of
sFlt-1 and the values of the sFlt-1 to 25(OH)D ratio in
Polish women with physiological pregnancies and preg-
nancies complicated by GH, PE, and GDM. Identiﬁcation
of a link between the sFlt-1 level and the risk of pregnancy
complications could play an important role in the predic-
tion of their occurrence, thus, contributing to better out-
comes in pregnant women and their oﬀspring.
2. Materials and Methods
The study, conducted in 2013-2015 at the Department of
Obstetrics and Gynecology, Ludwik Rydygier Collegium
Medicum in Bydgoszcz, Nicolaus Copernicus University of
Torun, included 207 women with singleton pregnancies (all
Caucasians of Polish nationality, residents of Kuyavian-
Pomeranian Province). The age of the study participants
ranged between 19 and 40 years.
The study group included 171 women—45 patients
with GH, 23 with PE, and 103 with GDM. Women who
presented with concomitant GH and GDM were excluded
from the study. GH was deﬁned as a systolic blood pressure
> 140mmHg or diastolic blood pressure > 90mmHg on
two or more measurements at least six hours apart, occur-
ring after 20 weeks of gestation, without concomitant pro-
teinuria. PE was deﬁned as the onset of hypertension
(systolic blood pressure ≥ 140mmHg or diastolic blood
pressure ≥ 90mmHg) in a previously normotensive woman,
coexisting with proteinuria (at least 0.3 g of protein in a 24-
hour urine sample) without a concomitant urinary tract
infection. GDMwas detected based on the result of a 75 g oral
glucose tolerance test (OGTT) conducted between 24 and 28
weeks of gestation. Women with GDM were stratiﬁed
according to the type of this condition, G1 or G2, in line with
the White classiﬁcation [6]. Type A1 (corresponding to
GDM G1) was deﬁned as an abnormal result of OGTT,
normal blood glucose levels during fasting and one/two
hours after a meal, and the ability to control glycemia
solely with a dietary modiﬁcation. Type A2 (corresponding
to GDM G2) was deﬁned as an abnormal result of OGTT,
abnormal glucose levels during fasting and/or after a meal,
and the inability to control glycemia without additional
therapy with insulin or other agents. All study patients
presented with appropriate-for-gestational-age (AGA)
pregnancies. Women after in vitro fertilization, as well as
those with comorbidities, were excluded from the study.
Serum concentrations of sFlt-1 and 25(OH)D were deter-
mined during hospital stay shortly before delivery. Women
who presented with abnormal blood pressure were addi-
tionally examined for the severity of GH and the presence
of PE. Other clinicodemographic variables included in the
analysis were maternal age, parity, body mass index
(BMI), gestational age at delivery, route of delivery, birth
weight, and pH of the umbilical cord blood. The control
group included 36 women with uncomplicated pregnan-
cies, normal arterial blood pressure, and glucose concen-
trations. All blood samples were obtained in the third
trimester, 1-7 days before delivery. All controls were
matched for the gestational age.
2.1. Methods. 10ml blood samples were obtained from the
cubital vein and immediately separated by centrifugation.
The sera were stored at -80°C until the analysis. Serum
concentrations of sFlt-1 were determined with the fully
automated Elecsys® electrochemiluminescence assay (Roche
Diagnostics, Manheim, Germany). The assay was performed
using Roche immunoanalyzer Elecsys® 2010/cobas e411, in
line with the manufacturer’s instruction. The detection range
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of the assay was 10-85 000 pg/ml, and the limit of quantiﬁca-
tion amounted to 15 pg/ml. Interassay coeﬃcient of variation
(CV) for the sFlt-1 assay was 4.3% at a mean concentration of
98 pg/ml (PreciControl Multimarker 1, Roche Diagnostics,
Manheim, Germany) and 3.8% at 1 020 pg/ml (PreciControl
Multimarker 2, Roche Diagnostics, Manheim, Germany).
The limit of detection for the test was 10 pg/ml. Serum
25(OH)D concentration was determined by ELISA (25-
hydroxy vitamin D EIA), Immunodiagnostic Systems Ltd.,
in the Department of Laboratory Diagnostics, Ludwik Rydy-
gier Collegium Medicum, Nicolaus Copernicus University in
Torun; the sensitivity was 2.0 ng/ml (5 nmol/l) and the assay
measured range was 2.7–152ng/ml (6.8–380nmol/l). A
certiﬁed reference material (NIST Standard Reference Mate-
rial (SRM) 972) was used for vitamin D measurement. The
method remained under RIQAS control, and the results of
the assay are within the reference range for this control.
The inter- and intraassay variabilities were 5.3% and 4.6%.
A concentration of 25 OH D < 10 ng/ml (<25nmol/l) was
deﬁned as deﬁciency, 10–29 ng/ml (25–74nmol/l) has been
accepted as insuﬃciency, and suﬃcient was when concentra-
tions were between 30 and 100ng/ml (75–250nmol/l). In our
previous study, we presented levels of serum vitamin D levels
in all study subgroups [16].
2.2. Statistical Analyses. Statistical analyses were carried out
with PQStat software, version 1.6. The signiﬁcance of inter-
group diﬀerences in sFlt-1 concentrations was veriﬁed with
Mann-Whitney U test and Kruskal-Wallis test with Dunn’s
post hoc tests. Direction and power of relationships between
serum sFlt-1, maternal age, pH of the umbilical cord blood,
and birth weight were estimated based on Spearman’s coeﬃ-
cients of rank correlation. Statistical signiﬁcance of potential
predictors of GH, PE, and GDM were veriﬁed in univariate
and multivariate models of logistic regression. The roles of
sFlt-1 and the sFlt-1 to 25(OH)D ratio as predictors of GH
and PE were additionally veriﬁed on ROC analysis. The
results of all the tests were considered signiﬁcant at p < 0 05
and highly signiﬁcant at p < 0 01.
The protocol of the study was approved by the Local
Bioethics Committee at Ludwik Rydygier Collegium Medi-
cum in Bydgoszcz (decision no. KB 502/2013), and written
informed consent was sought from all participants.
3. Results
Patient age, parity, BMI, gestational age at delivery, route of
delivery, birth weight, and pH of the umbilical cord blood
were analyzed. The control group included 36 women with
uncomplicated pregnancies, normal arterial blood pressure,
and glucose concentrations. Baseline characteristics of study
participants are presented in Table 1.
Women with GH diﬀered signiﬁcantly from the con-
trols in terms of their sFlt-1 concentrations (5797 pg/ml
vs. 3531pg/ml, p = 0 0014; Table 2). Similarly, a signiﬁcant
diﬀerence was found between sFlt-1 concentrations in
women with PE and the controls (6074 pg/ml vs. 3531 pg/ml,
p < 0 0001; Table 3). However, no statistically signiﬁcant
diﬀerences were observed between sFlt-1 concentrations in
women with GDM G1, women with GDM G2 and the con-
trols (4301 pg/ml vs. 3704 pg/ml vs. 3531pg/ml, p = 1 0000;
Table 4).
While we must admit that our control group was rela-
tively small (N = 36), the results for this group are consistent
with those reported by other authors and ﬁt within published
reference limits for the third trimester [17].
Table 5 presents sFlt-1 concentrations stratiﬁed accord-
ing to arterial pressure of the study participants. The levels
of sFlt-1 increased with blood pressure and were the highest
in the group of patients whose blood pressure exceeded
180/110mmHg.
We also compared sFlt-1 levels in the groups of
patients with adequate serum concentrations of 25(OH)D
(≥20 ng/mL) and vitamin D deﬁciency. The results are
presented in Table 6. The concentrations of sFlt-1 in
patients with adequate serum levels of 25(OH)D
(≥20 ng/ml) turned out to be signiﬁcantly lower than in
those with vitamin D insuﬃciency/deﬁciency (3356 pg/ml
vs. 4452 pg/ml, p = 0 0256).
Table 1: Baseline characteristics of the study participants.
Parameter
Study group
(N = 171)
Control group
(N = 36) p
Age (years) 29 6 ± 5 2 29 4 ± 4 9 NS
BMI (kg/m2) 27, 8 ± 2, 2 26, 9 ± 2, 4 NS
Parity 1 9 ± 1 1 1 8 ± 1 0 NS
pH of umbilical artery 7 35 ± 0, 09 7, 35 ± 0 07 NS
BMI (kg/m2) 24, 8 ± 2, 0 25, 2 ± 2, 5 NS
Pregnancy (weeks) 38 ± 2, 96 40 ± 1, 08 NS
Caesarian sections (%) 43,3% 37,6% NS
Weight of newborn (g) 3340 ± 680 3590 ± 430 NS
Systolic blood
pressure (mmHg)
126,8 ± 13, 5 120,2 ± 9, 1 NS
Diastolic blood
pressure (mmHg)
80, 3 ± 10, 3 76, 9 ± 8, 6 NS
GH status N = 45 N = 0 —
Preeclampsia status N = 23 N = 0 —
GDM status N = 103 N = 0 —
Table 2: sFlt-1 concentration (pg/ml) in the group of patients with
hypertension and the control group.
sFlt-1 (pg/ml)
Gestational
hypertension
(N = 45)
Control group
(N = 36) p value
Median range 5797 (4746-10277) 3531 (2672-4980) p = 0 0014
Table 3: sFlt-1 concentration (pg/ml) in the group of women with
preeclampsia and the control group.
sFlt-1 (pg/ml)
Preeclampsia
(N = 23)
Control group
(N = 36) p value
Median range 6074 (5273-12448) 3531 (2672-4980) p < 0 0001
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Then, we conducted a series of ROC analyses to verify
whether sFlt-1 and the sFlt-1 to 25(OH)D ratio were signiﬁ-
cant predictors of GH and PE. The results are presented in
Tables 7 and 8. Serum sFlt-1 turned out to be a signiﬁcant
predictor of GH (p = 0 001) and PE (p < 0 0001), with AUC
equal 70.1% and 82.4, respectively (Figures 1 and 2). Also,
the sFlt-1 to 25(OH)D ratio was identiﬁed as a signiﬁcant
predictor of both GH (p < 0 0001) and PE (p < 0 0001), with
AUC amounting to 73.6% and 87.96%, respectively
(Figures 3 and 4). In our present study, the serum sFlt-1 to
25(OH)D ratio (with the cutoﬀ value of 652) was identiﬁed
as a good predictor of GH on ROC analysis (p < 0 0001), with
an AUC equal 73.6%. Moreover, the serum sFlt-1 to
25(OH)D ratio (with a similar cutoﬀ value as above, 653)
turned out to be a signiﬁcant predictor of PE (p < 0 0001),
with an AUC equal 87.96%.
Finally, multivariate logistic regression analysis was
conducted to verify if serum sFlt-1 predicted GH and PE
independently from other established risk factors
(BMI ≥ 30 kg/m2, age ≥ 35 years, primiparity) and low vita-
min D levels. The results are presented in Tables 9 and 10.
On multivariate logistic regression analysis, 25(OH)D was
not identiﬁed as an independent predictor of either hyper-
tension or preeclampsia (p > 0 05). The analysis identiﬁed
serum sFlt-1 and BMI ≥ 30 kg/m2 as independent predic-
tors of GH. Furthermore, serum sFlt-1 turned out to be
an independent predictor of PE on multivariate logistic
regression analysis.
4. Discussion
Impaired synthesis of placental biomarkers and vitamin D
deﬁciency have been postulated as risk factors of many
pregnancy pathologies; however, in the case of many such
relationships, the exact pathogenic mechanisms are not fully
understood. A growing body of evidence suggests that
endothelial dysfunction may play an important role in the
pathogenesis of many pregnancy complications [18].
VEGFs are essential for proper implantation of the pla-
centa. Soluble type 1 receptor for VEGF (soluble fms-like
tyrosine kinase 1 (sFlt-1)) probably plays an important role
in many processes occurring during pregnancy, modulating
function of VEGFs [19]. Placental ischemia was shown to
be associated with the production of factors contributing to
endothelial dysfunction, among them sFlt-1; the dysfunction
of vascular endothelium can manifest as arterial hyperten-
sion and proteinuria [20–22].
Considering the results of many previous studies that
documented the link between the sFlt-1 status and the occur-
rence of pregnancy pathologies, we veriﬁed whether a similar
Table 4: sFlt-1 concentration (pg/ml) in the group of patients with gestational diabetes and the control group.
sFlt-1 (pg/ml) GDM G1 (N = 19) GDM G2 (N = 84) Control group (N = 36) p value
Median range 4301 (2384-5977) 3704 (2403-5153) 3531 (2673-4980) p = 1 0000
Table 5: sFlt-1 concentration (pg/ml) in relation to blood pressure.
sFlt-1 (pg/ml)
RR > 140/90 RR > 160/100 RR > 180/110 Control group
Median 5399 5880 6074 3531
Range (4048–8232) (4443–9239) (5176–12325) (2672–4980)
p value (vs. the control group) 0.0055 0.0015 0.0059
Table 6: sFLT-1 levels in the group of patients with suﬃcient serum
concentrations of 25(OH)D (>20 ng/ml) and with vitamin D
insuﬃciency/deﬁciency (25 OH D ≤ 20 ng/ml).
sFlt-1 (pg/ml)
25 OH D ng/ml ≤ 20 25 OH D ng/ml > 20
Median 4452 3356
Range (3137.5–6066.75) (2447–5284)
p value 0.0256
Table 7: Relationships between serum concentrations of sFlt-1 and
the incidence of gestational hypertension (GH) and preeclampsia
(PE); results of ROC (receiver operating characteristic) analysis.
Parameter GH PE
AUC 0.7012 0.8237
SE (AUC) 0.0489 0.0488
-95% CI 0.6055 0.7280
+95% CI 0.7970 0.9194
Z-statistic 3.9942 4.9837
p 0.0001 <0.0001
Cutoﬀ value 9643 10488
Table 8: Relationship between serum concentrations of sFlt-
1/25(OH)D index and the incidence of gestational hypertension
(GH) and preeclampsia (PE); results of ROC analysis.
Parameter GH PE
AUC 0.7359 0.8796
SE (AUC) 0.0483 0.0354
-95% CI 0.6413 0.8101
+95% CI 0.8306 0.9490
Z-statistic 4.5472 5.6978
p <0.0001 <0.0001
Cutoﬀ value 652.37 653.19
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relationship existed in Polish women with GH. Our study
showed that sFlt-1 concentrations in women with GH were
signiﬁcantly higher than in those with physiological pregnan-
cies (5797 pg/ml vs. 3531pg/ml, p = 0 0014) and serum sFlt-1
was identiﬁed as a signiﬁcant predictor of GH on both
logistic regression analysis and ROC analysis. On ROC
analysis, serum sFlt-1 turned out to be a signiﬁcant predic-
tor of GH (p = 0 001), with an AUC equal 70.1%. Further-
more, multivariate logistic regression analysis identiﬁed
elevated serum sFlt-1 and BMI ≥ 30 kg/m2 as independent
predictors of GH.
Our ﬁndings are consistent with the results published by
Nanjo et al. [23] who demonstrated that prior to delivery,
women with GH presented with signiﬁcantly higher sFlt-1
levels than those without. Moreover, they found a signiﬁcant
correlation between the levels of circulating angiogenic fac-
tors shortly before delivery and the severity of hypertensive
disorders in pregnancy [23]. Also, in our study, sFlt-1 con-
centrations increased with maternal blood pressure and were
the highest in patients with arterial pressure exceeding
180/110mmHg. This might be another argument for a role
of sFlt-1 in endothelial damage. Possibly, the higher the
blood pressure, the greater the endothelial damage and the
more elevated the sFlt-1 levels. Our ﬁndings are consistent
with the results of many previously published studies [24].
According to Verlohren et al., the sFlt-1/PlGF ratio allowed
the identiﬁcation of women at risk for imminent delivery
and was a reliable tool to discriminate between various types
of pregnancy-related hypertensive disorders [24].
Both available evidence and our present ﬁndings imply
that sFlt-1 plays an important role in the pathogenesis of
GH and PE, as well as in the clinical course of these condi-
tions [25]. PE is diagnosed whenever a pregnant woman pre-
sents with hypertension and concomitant proteinuria. The
proteinuria may be a consequence of glomerular damage
which can be caused by binding sFlt-1 to VEGF and resultant
destruction of vascular endothelium. The same mechanism
may also be involved in glomerular damage in patients with
GDM [26].
In this context, it is not surprising that patients with PE
presented with the highest sFlt-1 concentrations of all preg-
nant women participating in our study. The concentration
of sFlt-1 in the PE group turned out to be signiﬁcantly higher
than in the controls (6074 pg/ml vs. 3531 pg/ml, p < 0 0001).
Furthermore, serum sFlt-1 was identiﬁed as a signiﬁcant
determinant of PE on ROC analysis (p < 0 0001), with AUC
equal 82.4%. Serum sFlt-1 was also identiﬁed as an indepen-
dent predictor of PE on multivariate logistic regression
analysis. The elevated serum level of sFlt-1 was shown to be
associated with higher risk of PE. sFlt-1 is known to
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Figure 1: ROC curve—relationship between sFlt-1 concentrations (pg/ml) and occurrence of gestational hypertension (AUC 70.1%).
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contribute to endothelial damage, and hence, an increase in
its concentration may negatively aﬀect vascular integrity.
The role of sFlt-1 in PE was a subject of many previous stud-
ies. Agrawal et al. conducted a meta-analysis to explore the
predictive value of the sFlt-1/PlGF ratio in preeclampsia.
The meta-analysis included 15 studies with a total of 534
cases of preeclampsia and 19587 controls. The sFlt-1/PlGF
ratio had a pooled sensitivity of 80% (95% conﬁdence inter-
val, 0.68-0.88), speciﬁcity of 92% (95% conﬁdence interval,
0.87-0.96), positive likelihood ratio of 10.5 (95% conﬁdence
interval, 6.2-18.0), and a negative likelihood ratio of 0.22
(95% conﬁdence interval, 0.13-0.35) in predicting pre-
eclampsia in both high- and low-risk patients. According to
the authors of the meta-analysis, these ﬁndings imply that
the sFlt-1/PlGF is a valuable screening tool for preeclampsia
and might be helpful in decision-making, treatment stratiﬁ-
cation, and better resource allocation [27].
A recent prospective multicenter observational study
PROGNOSIS (prediction of short-term outcome in pregnant
women with suspected preeclampsia study) was designed to
analyze the serum sFlt-1 to placental growth factor (PlGF)
ratio as a predictor of PE during a short-term follow-up of
women with singleton pregnancies (24 weeks and 0 days to
36 weeks and 6 days of gestation) suspected of this condition
[28]. The study demonstrated that the sFlt-1 to PlGF ratio of
38 or less might be used to exclude PE in a short-term per-
spective in women suspected of this condition based on clin-
ical presentation.
Although the role of the sFlt-1 to PlGF ratio raises no
controversies, we still need more data about other potential
predictors of GH and PE. Speciﬁcally, a reliable predictor of
PE (and in particular the absence thereof) is needed in
women with clinical suspicion of this pregnancy complica-
tion. Many women whose clinical presentation raises a
suspicion of PE are hospitalized until this condition and
other adverse outcomes have been excluded. At the same
time, PE may be overlooked in other pregnant women who
should be hospitalized. Although no preventive or therapeu-
tic strategy for PE is yet available except low-dose acetylsa-
licylic acid treatment which was shown to exert a moderate
preventive eﬀect on high-risk pregnancies after the ﬁrst tri-
mester, clinical experience suggests that early detection and
monitoring could be beneﬁcial. Therefore, based on pub-
lished evidence including the results of our previous study
[16], we decided to verify whether sFlt-1 and 25(OH)D
concentrations might be used as the measures of GH and
pH risk. Our study demonstrated that women with adequate
serum levels of 25(OH)D (≥20 ng/ml) presented with
signiﬁcantly lower levels of sFlt-1 than those with vitamin
D deﬁciency (3356 pg/ml vs. 4452 pg/ml, p = 0 0256). This
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Figure 2: ROC curve—relationship between sFlt-1 concentrations (pg/ml) and occurrence of preeclampsia (AUC 82.4%).
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observation is consistent with the results published by Zeisler
et al. [28]. According to those authors, 25(OH)D concentra-
tions in women diagnosed with PE were signiﬁcantly lower
than those in patients without this condition and a low level
of 25(OH)D was associated with increased risk of late-onset
PE (odds ratio 4.6, 95% conﬁdence interval 1.4-15). Interest-
ingly, however, no similar association was found for early-
onset PE. Furthermore, the study did not demonstrate a link
between the 25(OH)D level and the sFlt-1 to PlGF ratio.
Based on those ﬁndings, Álvarez-Fernández et al. concluded
that low concentration of vitamin D in women with sus-
pected late-onset PE is associated with increased risk of the
imminent disease [29].
In our present study, the serum sFlt-1 to 25(OH)D ratio
(with the cutoﬀ value of 652) was identiﬁed as a good predic-
tor of GH on ROC analysis (p < 0 0001), with an AUC equal
73.6%. Moreover, the serum sFlt-1 to 25(OH)D ratio (with a
similar cutoﬀ value as above, 653) turned out to be a signiﬁ-
cant predictor of PE (p < 0 0001), with an AUC equal
87.96%. Based on these ﬁndings, it can be speculated that
sFlt-1 and 25(OH)D not only play an important role in the
pathogenesis of GH and PE but can also be used as predictors
thereof. A similar character of relationships between sFlt-1
and 25(OH)D levels and the risk of GH and PE might be
explained by the fact that both those factors interfere with
vascular endothelium [30]. However, in our present study,
25(OH)D did not turn out to be an independent predictor
of either hypertension or preeclampsia on multivariate logis-
tic regression analysis (p > 0 05).
The authors of one previous study, Ma et al. [31], veriﬁed
whether vitamin D supplementation alleviated PE-associated
endothelial dysfunction and explored the underlying mecha-
nism of this relationship using a reduced uterine perfusion
pressure (RUPP) rat model. 1,25(OH)2D turned out to sig-
niﬁcantly downregulate the expression of placental sFlt-1 in
RUPP rats. Furthermore, circulating sFlt-1 levels in maternal
serum correlated positively with the expression of placental
sFlt-1 and returned to normal values after supplementation
with vitamin D. Based on those ﬁndings, the authors con-
cluded that vitamin D supplementation might have protected
against the RUPP-induced endothelial dysfunction by down-
regulating placental sFlt-1, which could plausibly alleviate
PE-related symptoms.
Another study, conducted by Song et al. [32], veriﬁed
whether vitamin D supplementation could restore angio-
genic balance and ameliorate inﬂammation in a rat model
for PE. Animals from the supplemented group presented
with signiﬁcantly higher concentrations of VEGF and signif-
icantly lower sFlt-1 and TNF-α levels than untreated rats
with PE. Therefore, the authors concluded that vitamin D
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Figure 3: ROC curve—relationship between sFlt-1/25(OH)D index and occurrence of gestational hypertension (AUC 73.6%).
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Figure 4: ROC curve—relationship between sFlt-1/25(OH)D index and occurrence of preeclampsia (AUC 87.96%).
Table 9: Results of multivariate logistic regression analyses examining the eﬀects of serum sFlt-1 levels (pg/ml), BMI ≥ 30, age ≥ 35,
primiparity, and 25 OH D ≤ 20 ng/ml on the incidence of hypertension.
Parameter b-coeﬃcient p value Odds ratio -95% CI +95% CI
Intercept -2.7821 0.0071 0.0619 0.0082 0.4687
sFlt-1 (pg/ml) 0.0004 0.0170 1.0004 1.0001 1.0007
BMI ≥ 30 2.7985 0.0003 16.4199 3.5615 75.7012
Age ≥ 35 years -0.5656 0.5221 0.5680 0.1005 3.2093
Primiparity 0.6656 0.3842 1.9456 0.4345 8.7132
25 OH D ≤ 20 ng/ml 0.1091 0.8875 1.1153 0.2459 5.0592
Table 10: Results of multivariate logistic regression analyses examining the eﬀects of serum sFlt-1 levels (pg/ml), BMI ≥ 30, age ≥ 35,
primiparity, and 25 OH D ≤ 20 ng/ml on the incidence of preeclampsia.
Parameter b-coeﬃcient p value Odds ratio -95% CI +95% CI
Intercept -5.6590 <0.0001 0.0035 0.0005 0.0250
sFlt-1 (pg/ml) 0.0004 0.0001 1.0004 1.0002 1.0006
BMI ≥ 30 0.6718 0.2829 1.9578 0.5745 6.6724
Age ≥ 35 years -1.5500 0.2223 0.2122 0.0176 2.5585
Primiparity 0.9548 0.1540 2.5982 0.6991 9.6559
25 OH D ≤ 20 ng/ml 1.0028 0.1331 2.7259 0.7365 10.0883
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supplementation might play an important role in the restora-
tion of angiogenic balance and attenuation of inﬂammation
in pregnancy-induced hypertension [32].
Schulz et al. [33] demonstrated that sFlt-1 and VEGF
gene expressions in the maternal subgroup with circulating
25 OH D ≥ 100 ng/ml were signiﬁcantly downregulated
compared to the subgroup with 25 OH D < 100 ng/ml.
Moreover, they found a signiﬁcant association between the
maternal vitamin D status and the expressions of sFlt-1 and
VEGF at the mRNA level. Based on those ﬁndings, the
authors stated that maternal supplementation with vitamin
D3 may exert an eﬀect on gene transcription in the placenta
and, thus, may reduce the level of antiangiogenic factors that
are implicated in vascular pregnancy complications [33].
Only few previous studies analyzed sFlt-1 levels in
women with GDM, and their results are inconclusive. In
our present study, we found no diﬀerences in sFlt-1 levels
in the GDM G1 and GDM G2 groups and the controls
(4301 pg/ml vs. 3704 pg/ml vs. 3532 pg/ml, p = 1 00). One
potential explanation for this phenomenon might be the fact
that our patients with GDM still did not develop an endothe-
lial damage, and thus, their sFlt-1 concentrations remained
within the normal range. In our opinion, no ultimate conclu-
sions can be formulated on the role of sFlt in GDM and this
issue needs to be addressed in further studies [34].
In conclusion, this study showed that determination of
the sFlt-1 to 25(OH)D ratio may facilitate the identiﬁcation
of patients with preeclampsia and gestational hypertension
and their qualiﬁcation for intensive treatment, which can be
reﬂected by better neonatal outcomes.
The results of our study, which can be considered prelim-
inary ﬁndings, justify further clinical research on a larger
group of patients, including measurements of vitamin D con-
centrations to calculate the ratio derived from this parameter
aside from that based on sFLT-1 and PLGF levels.
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